NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

NV-387 mimics HSPG, presents itself as a decoy to the virus, and is capable of destroying the virus particle thereby stalling ... Dengue fever, and Ebola virus, among others.

Promega technology will support a collaboration between Charles River and CEPI's Centralised Laboratory Network aimed at ...

“You’re not trying to see the scattered light from the virus particle itself, but you’re looking at the interferometric signature of the field of scattered light mixed with the field that is ...

With a viral vector, there is essentially a viral particle, which is programmed not ... killing them before the virus spreads. “With the initial single dose of Convidecia, we have over 90% ...

Filoviruses are among the globe's most lethal—indeed, so dangerous they can be handled only in high-security laboratories.

A team of scientists has uncovered the remarkable potential of a human antibody, mAb 3A6, in fighting Ebola virus infections.